Navigation Links
Study examines effects of genetic variants for infants with neonatal abstinence syndrome
Date:4/30/2013

Among infants with neonatal abstinence syndrome (NAS; caused by in utero opioid exposure), variants in certain genes were associated with a shorter length of hospital stay and less need for treatment, preliminary findings that may provide insight into the mechanisms underlying NAS, according to a study in the May 1 issue of JAMA, a theme issue on child health.

Jonathan M. Davis, M.D., of The Floating Hospital for Children at Tufts Medical Center, Boston, presented the findings of the study at a JAMA media briefing.

"In the past decade, there has been a significant increase in opioid use during pregnancy, estimated to affect 5.6 per 1,000 births," according to background information in the article. Neonatal abstinence syndrome is a disorder composed of a constellation of signs and symptoms involving dysfunction of the nervous system, gastrointestinal tract, and respiratory system because of in utero drug exposure or iatrogenic (due to therapy) withdrawal after maternal use of drugs for pain control during pregnancy. "The incidence of NAS has tripled in the past decade, affecting 60 percent to 80 percent of infants born to mothers receiving methadone or buprenorphine. Although clinical factors, including maternal smoking, psychiatric medications, and breastfeeding, can affect the incidence and severity of NAS, to our knowledge contributing genetic factors influencing NAS have not been previously identified."

Variations in the genes OPRM1, ABCB1, and COMT are associated with risk for opioid addiction in adults. Dr. Davis and colleagues conducted a study to determine whether genomic variations in these genes are associated with length of hospital stay (LOS) and the need for treatment of NAS. The study was conducted at 5 tertiary care centers and community hospitals in Massachusetts and Maine between July 2011 and July 2012. DNA samples were genotyped for single-nucleotide polymorphisms (SNPs), and NAS outcomes were correlated with genotype.

Eighty-six of 140 eligible mother-infant dyads (pairs) were enrolled. Infants were eligible if they were 36 weeks' gestational age or older and exposed to methadone or buprenorphine in utero. Eighty-one (94 percent) of the mothers were receiving opioid substitution therapy from the first trimester, with 17 (20 percent) relapsing into illicit drug use during the third trimester. Average LOS for all infants was 22.3 days; for treated infants, 31.6 days. Fifty-six (65 percent) of all infants were treated for NAS.

The researchers found that infants with the OPRM1 118A>G AG/GG genotype had shortened length of stay (-8.5 days [calculated with linear regression models]) and were less likely to receive any treatment than infants with the AA genotype (48 percent vs. 72 percent). "The COMT 158A>G AG/GG genotype was associated with shortened length of stay (-10.8 days) and less treatment with 2 or more medications (18 percent vs. 56 percent) than the AA genotype. Associations with the ABCB1 SNPs were not significant."

"To our knowledge, this is the first study to examine the association of genomics with opioid withdrawal in infants and may provide insight into the mechanisms underlying NAS. There is a need for replication of these results before more definitive conclusions can be made of the association between the OPRM1 and COMT variants and NAS," the authors conclude.


'/>"/>

Contact: Julie Jette
jjette@tuftsmedicalcenter.org
617-636-3265
The JAMA Network Journals
Source:Eurekalert

Related biology news :

1. University of Houston engineering professor awarded grant to study melanoma treatment
2. Monoclonal Antibody with Xencors High ADCC Fc Technology Enters Phase 2 Study in B-cell Acute Lymphoblastic Leukemia
3. BUSM study reveals novel mechanism by which UVA contributes to photoaging of skin
4. Study led by NUS scientists reveals escalating cost of forest conservation
5. Rescue me: New study finds animals do recover from neglect
6. Genome study suggests new strategies for understanding and treating pulmonary fibrosis
7. Hop, skip or jump? Study says no to all of the above
8. Federal Government Organization achieves cleaner and faster Clinical Study Data using Tablet PCs from TabletKiosk
9. Half of Tamiflu prescriptions went unused during 2009 H1N1 swine flu pandemic, UK sewage study
10. CU-Boulder study looks at microbial differences between parents, kids and dogs
11. TGen-led study discovers dramatic changes in bacteria following male circumcision
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2021)... ... March 25, 2021 , ... Phlexglobal announced ... Planet Group, has selected Phlexglobal and its innovative regulatory SaaS software, PhlexSubmission, as ... a comprehensive review of five regulatory software companies, with the review team including ...
(Date:3/27/2021)... ... 25, 2021 , ... The 2021 Virtual Conference on Clinical Trial Supply-Europe ... More and more, clinical trial supply conferences are featuring speakers and forums that ... Asymmetrex’s founder and CEO, James L. Sherley, M.D., Ph.D., presented a talk ...
(Date:3/23/2021)... ... March 23, 2021 , ... G-CON Manufacturing (G-CON), the ... by Matica Biotechnology (Matica Bio), a contract development and manufacturing organization (CDMO) specializing ... the cleanroom build out for its new GMP production facility in College Station, ...
Breaking Biology News(10 mins):
(Date:3/27/2021)... ... March 24, 2021 , ... ... Life Sciences and Healthcare firms of all sizes, adds depth to its team ... specialist. Pardillo, who earned his doctorate in computational chemistry from Florida International University ...
(Date:3/27/2021)... ... March 24, 2021 , ... ABI Wellness, ... and reporting approach designed under CEO Mark Watson, today announced a webinar dedicated ... featuring guest speakers Dr. Cameron Clark, Neuropsychologist and Founder of Sharp Thinking, and ...
(Date:3/27/2021)... ... ... The Xtalks editorial team is pleased to announce the launch of the ... joined by editorial team members Ayesha Rashid, Sydney Perelmutter and Mira Nabulsi to discuss ... including insights from industry experts. , The Xtalks Life Science podcast will feature ...
(Date:3/23/2021)... Conn. (PRWEB) , ... March 23, 2021 , ... ... develops solutions for characterizing microbiome populations down to the strain level, recently unveiled ... applications. , Not all microbes are created equal: some are easy to ...
Breaking Biology Technology: